150 related articles for article (PubMed ID: 27116898)
21. Decorating sdAbs with Chelators: Effect of Conjugation on Biodistribution and Functionality.
Baudhuin H; Puttemans J; Hanssens H; Vanwolleghem P; Hernot S; Raes G; Xavier C; Lahoutte T; Debie P
Pharmaceuticals (Basel); 2021 Apr; 14(5):. PubMed ID: 33923088
[TBL] [Abstract][Full Text] [Related]
22. Selection, characterization, and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein.
Liu JL; Shriver-Lake LC; Anderson GP; Zabetakis D; Goldman ER
Microb Cell Fact; 2017 Dec; 16(1):223. PubMed ID: 29233140
[TBL] [Abstract][Full Text] [Related]
23. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Bannas P; Hambach J; Koch-Nolte F
Front Immunol; 2017; 8():1603. PubMed ID: 29213270
[TBL] [Abstract][Full Text] [Related]
24. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics.
Mujić-Delić A; de Wit RH; Verkaar F; Smit MJ
Trends Pharmacol Sci; 2014 May; 35(5):247-55. PubMed ID: 24690241
[TBL] [Abstract][Full Text] [Related]
25. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
26. Recombinant Antibody Fragments for Neurodegenerative Diseases.
Manoutcharian K; Perez-Garmendia R; Gevorkian G
Curr Neuropharmacol; 2017; 15(5):779-788. PubMed ID: 27697033
[TBL] [Abstract][Full Text] [Related]
27. Designer genes: recombinant antibody fragments for biological imaging.
Wu AM; Yazaki PJ
Q J Nucl Med; 2000 Sep; 44(3):268-83. PubMed ID: 11105590
[TBL] [Abstract][Full Text] [Related]
28. Characterization of single-domain antibodies against Foot and Mouth Disease Virus (FMDV) serotype O from a camelid and imaging of FMDV in baby hamster kidney-21 cells with single-domain antibody-quantum dots probes.
Wang D; Yang S; Yin S; Shang Y; Du P; Guo J; He J; Cai J; Liu X
BMC Vet Res; 2015 May; 11():120. PubMed ID: 26001568
[TBL] [Abstract][Full Text] [Related]
29. Introduction to heavy chain antibodies and derived Nanobodies.
Vincke C; Muyldermans S
Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
[TBL] [Abstract][Full Text] [Related]
30. [Progress in nanobody and its application in diagnosis].
Kong Q; Yao Y; Chen R; Lu S
Sheng Wu Gong Cheng Xue Bao; 2014 Sep; 30(9):1351-61. PubMed ID: 25720150
[TBL] [Abstract][Full Text] [Related]
31. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
[TBL] [Abstract][Full Text] [Related]
32. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Biosensor Platforms for Detecting the Atherosclerotic Biomarker VCAM1 Based on Bioconjugation with Uniformly Oriented VCAM1-Targeting Nanobodies.
Ta DT; Guedens W; Vranken T; Vanschoenbeek K; Steen Redeker E; Michiels L; Adriaensens P
Biosensors (Basel); 2016 Jul; 6(3):. PubMed ID: 27399790
[TBL] [Abstract][Full Text] [Related]
34. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
35. Targeting dsRNA-specific single-chain Fv antibody fragments to different cellular locations in Nicotiana tabacum L.
Morgun B; Richter A; Deshmukh SD; Stepanyuk V; Kálai K; Nagy G; Hufnagel L; Lukács N
Acta Biol Hung; 2006 Jun; 57(2):247-59. PubMed ID: 16841475
[TBL] [Abstract][Full Text] [Related]
36. An altered camelid-like single domain anti-idiotypic antibody fragment of HM-1 killer toxin: acts as an effective antifungal agent.
Kabir ME; Krishnaswamy S; Miyamoto M; Furuichi Y; Komiyama T
Appl Microbiol Biotechnol; 2011 Apr; 90(2):553-64. PubMed ID: 21305279
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
38. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
Pain C; Dumont J; Dumoulin M
Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
[TBL] [Abstract][Full Text] [Related]
39. Modular Site-Specific Conjugation of Nanobodies Using Two Co-Associating Tags.
Moeglin E; Barret L; Chatton B; Donzeau M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430882
[TBL] [Abstract][Full Text] [Related]
40. Nanobodies® as inhaled biotherapeutics for lung diseases.
Van Heeke G; Allosery K; De Brabandere V; De Smedt T; Detalle L; de Fougerolles A
Pharmacol Ther; 2017 Jan; 169():47-56. PubMed ID: 27373507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
